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OBJECTIVE: There is ongoing discussion in the Nether-
lands about the introduction of hepatitis B (HepB) vacci-
nation into the national immunisation program. The pur-
pose of this study was to analyze the cost-effectiveness of
general vaccination of newborns in addition to the current
policy, screening of pregnant women and subsequent im-
munisation of newborns from HBsAg- mothers (“screen 
vaccinate”) in comparison with the current strategy of
screening only (“screening only”), from a health care
payer perspective. METHODS: The incidence of HepB
infection over the next 50 years was simulated with a dy-
namic model, describing a population of age 0–60 years,
with 6 sexual activity classes (both for hetero- and homo-
sexual groups). Immigration from more endemic countries
was modelled as yearly additional incidence of carriers in
the population. Progress of disease after infection was
computed with a Markov-chain model, that predicted fu-
ture patient numbers, life-time costs of infection, and life-
years lost after infection. The main outcome parameter
was cost per life-years gained. Costs (in 1999 EUR) and
effects were discounted at 4%. RESULTS: Cost per life
year gained appeared to be highly sensitive to the as-
sumed percentage of carriers among immigrants, vaccina-
tion costs and to discounting of effects. Cost per life year
gained in the screen  vaccinate scenario ranged from
approximately EUR 25,000 (6% carriers among immi-
grants) to EUR 75,000 (1% carriers among immigrants).
If effects were not discounted, cost per life year gained
were below EUR 9,000 in all models explored.
CONCLUSIONS: Compared to other interventions, hep-
atitis B vaccination is not cost-effective in low endemic
countries such as the Netherlands. However, this conclu-
sion depends heavily on the convention to discount ef-
fects at a similar rate as costs. The application of stan-
dard methodology is unfavourable for programs that
prevent negative health outcomes in the mid- to long-
term.
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OBJECTIVE: 1) To describe the frequency and distribu-
tion of hospital antibiotics use. 2) To evaluate the appro-
priateness of the prescription to diagnostic and therapeu-
tic criteria. METHODS: It is an observational cross-
sectional study of 411 clinical records obtained by ran-
dom sampling over all hospital discharges between 01/
01/99 al 31/09/99. Information was sought on the fol-
lowing variables: identification, diagnosis, process indi-
cators, treatment changes and causes, indicators of clini-
cal evolution, and diagnostic and prescription criteria.
The information was collected and reviewed by the au-
thors. Criteria of infection and those of appropriateness
of prescription were obtained from the Centres for Dis-
ease Control and others scientific societies. RESULTS:
Antibiotics prescription was registered on the clinical
record in 25% of cases; 49% of antibiotic treatments
were prescribed in the hospital, 30% of them were treat-
ment changes, while 51% of antibiotic treatments were
prescribed in the reference hospital. Amoxicillin-Clavu-
lanate combination and ofloxacin account for 88% of
the prescriptions in the HMN and 76% of the total anti-
biotic treatments. Between 44% and 61% of the diagno-
sis were adequate to the criteria, with a mean of 54%,
and between 91% and 100% were appropriate prescrip-
tions. Mean treatment length was 9.6 days, and only
14% of the urinary tract infection treatment length was
correct; an intravenous catheter was kept 80% of the
treatment. DISCUSSION: While most of the antibiotic
prescription in this study were appropriate to the clinical
diagnosis, only half of the diagnosis were in keep with
the diagnostic criteria used in this study and the urinary
tract infection as well as the intravenous duration treat-
ment appear to be long. The consequences of these find-
ings are increased cost and iatrogenia. The adequacy of
diagnosis to objective criteria and the duration on treat-
ment, especially intravenous treatment, are the main ar-
eas for improving. The recommended strategies are: 1)
utilization consensus 2) training programs 3) medical au-
dits 4) development of diagnostic and therapeutic criteria
adapted to the hospital.
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OBJECTIVES: Influenza is a highly contagious disease
that remains a major cause of morbidity and mortality in
Europe. The socio-economic impact of the disease is un-
derestimated. The study aimed to model options for in-
fluenza management in three European countries (France,
Germany, United Kingdom). METHODS: Cost-of-illness
(COI) and cost-effectiveness (CE) models were developed
to assess the economics of influenza prevention for de-
fined adult groups (employed people, elderly, high-risk
patients). The initial models were developed based on in-
ternational and UK published data. Treatment efficacy
and the general epidemiology of influenza were assumed
to be similar for the three countries. The adaptation of
the general models was based on: 1) a country specific lit-
erature review was performed to collect baseline models
parameters: patient demographics, epidemiology, attack
rate, occurrence probabilities, complications and death,
current treatment patterns, general and specific clinical
practice guidelines, clinical effectiveness of current thera-
pies, medical resource utilization and productivity loss;
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2) two workshops in each country with a panel of local
influenza experts to validate the treatment patterns, to es-
timate missing values (event occurrences, transition prob-
abilities, hospitalization and indirect costs) and to ensure
the external validity of the local models. RESULTS: It
was possible to keep the general structure of the models
and to validate the basic assumptions. However, major
adaptations relating to influenza management and the as-
sociated costs were required. CONCLUSIONS: Even
though France, Germany and the UK have similar socio-
economic levels, the therapeutic and diagnostic manage-
ment of influenza differs between them. Indeed, the direct
transposition of a general model from one country to an-
other one is not possible: a cultural adaptation is re-
quired to make the model convincing, and therefore, use-
ful at a national policy level. These adaptations must
reflect differences in the patterns in service delivery, in in-
centives to patients and physicians, and in the propensity
to seek treatment.
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OBJECTIVE: Combination treatment with ribavirin and
interferon alpha-2b in treatment-naïve patients with chronic
hepatitis C virus produces an enhanced clinical response
compared with interferon alpha-2b treatment alone; add-
ing the second drug, however, will result in greater costs.
Clinical effects and costs for combination therapy were
compared to those for interferon alone in a cost-effective-
ness analysis for the Canadian healthcare environment.
METHODS: Data from an international clinical trial
comparing 24 and 48 weeks of combination therapy to
48 week interferon alone were applied to a previously
published model which tracked the health outcome of pa-
tients with chronic hepatitis C. Resource use and quality
of life was determined by a Canadian physician panel
and from patient-derived utility data; cost information in
1998 Canadian dollars was obtained from major health
centres across Canada and from published sources of Ca-
nadian cost data. RESULTS: Resource use by patients
with chronic hepatitis C can be minimal in the early
stages of the disease, progressing to hospitalization and
need for liver transplantation in the advanced stages. Ap-
plying dollar values to resource use, annual costs per dis-
ease state were found to range from under $200 per pa-
tient for the milder stages, up to greater than $90,000 per
patient for transplantation. For drug treatment, inter-
feron for 48 weeks cost $4,976 while combination ther-
apy for 24 weeks was $9,887 and for 48 weeks $12,840.
Modelling health outcomes over the course of the disease
along with costs for combination therapy compared to
interferon alone resulted in a marginal cost-effectiveness
ratio of $3,429 per discounted quality adjusted life year.
CONCLUSIONS: Results suggest that initial treatment
for chronic hepatitis C in Canada with 24 or 48 weeks of
combination therapy, when compared with 48 weeks of
interferon alone, should be cost-effective and economi-
cally attractive by conventional standards.
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OBJECTIVE: To pragmatically assess the effect of
HAART strategy on effectiveness and cost among unse-
lected HIV-infected persons. METHOD: We compared
two groups of patients followed at Rothschild public
hospital in Paris. We extracted longitudinal data from a
random sample of 99 ART-naïve patients in which a
HAART treatment was initiated between 10/1/96 and 4/
1/97 (HAART group). Each patient of the HAART group
was randomly matched for age, sex and CD4 cell count
to a corresponding control patient entered in the data-
base before the introduction of HAART, between 10/1/
94 and 4/1/95 (CONTROL group), whatever the treat-
ment was. The comparison criteria, on a two-year period,
are survival rate, immune recovery rate (CD4 count), op-
portunistic infections and use of resources (ART, other
treatment costs and hospital costs). RESULTS: 2-year
survival curves are similar in both groups (P  0.1502,
Log-Rank test). Immune recovery rate, at the end of the
follow-up, is significantly higher among HAART pa-
tients, with 35% vs. 13% with a CD4 count above 500/
mm3. Both mean and median CD4 cell counts are greater
in HAART group (344/mm3 and 320/mm3 vs. 280/mm3
and 245/mm3 respectively). The mean cost of ART is
higher in HAART group (171%). Nevertheless, this fi-
nancial charge is fully balanced by savings in other treat-
ment costs (62% largely due to less opportunistic infec-
tion treatments) and reduction in hospital costs (25%).
CONCLUSION: We pragmatically compared two groups
of HAART-treated and non-HAART-treated patients, re-
gardless of their disease stage. Results show the benefit of
